Etem Caliskan

Etem Caliskan

Auto-generated profile, based on publicly available information

Etem Caliskan

Department of Cardiovascular Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2019 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
ECEtem Caliskan
Etem Caliskan
DSDomingos Ramos de Souza
Domingos Ramos de Souza
ABAndreas Böning
Andreas Böning
OLOliver J. Liakopoulos
Oliver J. Liakopoulos
YCYeong-Hoon Choi
Yeong-Hoon Choi
MEMaximilian Y. Emmert
Maximilian Y. Emmert

22 August 2019 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Closed access
ECEtem Caliskan
Etem Caliskan
MEMatthias Eberhard
Matthias Eberhard
VFVolkmar Falk
Volkmar Falk
Hatem AlkadhiHatem Alkadhi
Hatem Alkadhi
MEMaximilian Y. Emmert
Maximilian Y. Emmert
OBJECTIVES: High success rates for left atrial appendage (LAA) exclusion with the AtriClip (Atricure, USA) device have been reported in the literature. This study evaluated the presence and characteristics of residual LAA stumps after AtriClip LAA exclusion using postoperative short- and long-term computed tomography angiography (CTA). METHODS: In this retrospective analysis, 43 of 291 consecutive patients undergoing cardiac surgery with concomitant LAA occlusion using the AtriClip device were identified with available postoperative short- and long-term follow-up by CTA. LAA patency and the absence or the size of a present residual LAA stump were assessed on 2-dimensional multiplanar reconstructions, on maximum intensity projection images and on volume-rendered 3-dimensional computed tomography reconstructions. Based on current recommendations, the threshold for a significant LAA stump length was defined <10 mm. RESULTS: The LAA was successfully occluded in all 43 patients (100%) as confirmed by intraoperative transoesophageal echocardiography and CTA imaging with a mean follow-up duration of 7.1 ± 0.8 years post-implant. The absence of blood flow in the excluded LAA was confirmed in all cases. In 31 of 43 patients (72%), no residual stump (0 mm) was observed creating a smooth endocardial surface, CTA revealed residual LAA stumps in 11/43 patients (26%) with a length 10 mm (12 mm) in 1 patient (2%). The mean length, width and depth of the residual stumps were 5.8 ± 2.1, 4.4 ± 1.2 and 7.3 ± 2.3 mm, respectively. CONCLUSIONS: This study investigated the incidence of residual stump formation (>10 mm) after LAA closure with the AtriClip device based on CTA imaging data obtained during short- and long-term follow-up. While no LAA stump was detectable in the majority of patients, a non-significant LAA stump (<10 mm) was present in 26% of cases, indicating a favourable LAA occlusion profile for the AtriClip device. However, although a LAA stump length <10 mm is currently considered clinically safe, this definition needs further attention in future studies with regards to its potential clinical implications.

31 January 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
MEMaximilian Y. Emmert
Maximilian Y. Emmert
RPRene Prêtre
Rene Prêtre
FRFrank Ruschitzka
Frank Ruschitzka
FKFranziska Krähenmann
Franziska Krähenmann
VFVolkmar Falk
Volkmar Falk
MWMarkus J. Wilhelm
Markus J. Wilhelm

23 September 2023 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
TNTimo Z. Nazari-Shafti
Timo Z. Nazari-Shafti
HTHenriette Thau
Henriette Thau
EZEma Zacharova
Ema Zacharova
CBChristien M Beez
Christien M Beez
VEVasileios Exarchos
Vasileios Exarchos
MEMaximilian Y Emmert
Maximilian Y Emmert
Despite the success of coronary artery bypass graft (CABG) surgery using autologous saphenous vein grafts (SVGs), nearly 50% of patients experience vein graft disease within 10 years of surgery. One contributing factor to early vein graft disease is endothelial damage during short-term storage of SVGs in inappropriate solutions. Our aim was to evaluate the effects of a novel endothelial damage inhibitor (EDI) solution, DuraGraft®, on SVGs from patients undergoing elective CABG surgery and on venous endothelial cells (VECs) derived from these SVGs. SVGs from 11 patients from an ongoing clinical registry (NCT02922088) were included in this study, and incubated with both full electrolyte solution (FES) or EDI for 1 h and then examined histologically. In 8 of 11 patients, VECs were isolated from untreated grafts, incubated with both FES and EDI for 2 h under hypothermic stress conditions, and then analyzed for activation of an inflammatory phenotype, cell damage and cytotoxicity, as well as endothelial integrity and barrier function. EDI was superior to FES in protecting the endothelium in SVGs (74 ± 8% versus 56 ± 8%, p < 0.001). Besides confirming that EDI prevents apoptosis in SVG-derived VECs, we also showed that EDI temporarily reduces adherens junctions in VECs while protecting focal adhesions compared to FES. EDI protects the connectivity and function of the SVG endothelium. Our data suggest that EDI can preserve focal adhesions in VECs during short-term storage after graft harvesting. This might explain the superiority of EDI in maintaining most of the endothelium in venous CABG surgery conduits.

1 September 2016 in EuroIntervention
Verified
Journal Article
Closed access
MTMaurizio Taramasso
Maurizio Taramasso
Azeem LatibAzeem Latib
Azeem Latib
PDPaolo Denti
Paolo Denti
FNFabian Nietlispach
Fabian Nietlispach
KLKevin Lynn
Kevin Lynn
FMFrancesco Maisano
Francesco Maisano
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

1 December 2023 in Interdisciplinary CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
HGHerko Grubitzsch
Herko Grubitzsch
ECEtem Caliskan
Etem Caliskan
TOTaoufik Ouarrak
Taoufik Ouarrak
JSJochen Senges
Jochen Senges
NDNicolas Doll
Nicolas Doll
GHGerd Hindricks
Gerd Hindricks
The CArdioSurgEry Atrial Fibrillation (CASE-AF) registry is a prospective, multicentre study for collecting and analysing real-world data of surgical atrial fibrillation (AF) treatment. This study aimed to evaluate outcomes of surgery for long-standing persistent AF at 1 year. In total, 17 centres consecutively include all eligible patients with continuous AF lasting for ≥1 year. Exclusion criteria are missing informed consent or age <18 years. For patient-reported outcomes measures, the European Heart Rhythm Association score was used. No presence of AF (based on ECG findings including Holter ECG and/or implanted devices), no re-ablation, no further cardioversion and no rehospitalization due to AF after a 3-month blanking period defined no AF recurrence at 1 year. From January 2017 to January 2020, a total of 1115 patients were enrolled in CASE-AF. Of them, 202 patients (mean age 69.7 ± 7.8 years, 27.2% female) underwent surgical ablation of long-standing persistent AF (study cohort), mostly accompanied by left atrial appendage closure (n = 180 [89%], resection n = 75 [42%]) and predominantly performed as concomitant (n = 174 [86%]) and left atrial only procedure (n = 144 [71%]). Early mortality (30 days) was 2.0% and morbidity was low. At follow-up (median 14.4 months, interquartile range, 12.7–17.6 months, 100% complete), 106 patients (56%) had no AF recurrence and 93% of them were asymptomatic. AF recurrence was accompanied by AF-related rehospitalization (n = 12, P = 0.003), direct current shock cardioversion (n = 23, P < 0.001), AF ablation (n = 7, P = 0.003) and stroke (n = 3, P = 0.059). Multivariable analysis identified cryoablation, predominantly performed endocardially including additional left atrial (74%) and biatrial (42%) lesions, as a significant factor for freedom from AF recurrence (odds ratio 2.7, 95% confidence interval 1.07–6.79, P = 0.035). According to CASE-AF, surgical ablation of long-standing persistent AF is most effective when concomitantly performed using endocardial cryoablation. Ongoing follow-up allows further elucidation of efficacious treatment strategies.